Terms ending in 2033
Every in-force patent on Allergan, Inc.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,992,668 | Injection Device In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 9,095,506 | Biodegradable ALPHA-2 Agonist Polymeric Implants and Therapeutic Uses Thereof In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 9,035,071 | Compounds Acting at Multiple Prostaglandin Receptors Giving a General Anti-Inflammatory Response In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 9,255,068 | Crystalline Salts of (4S,4AS,5AR,12AS)-4-Dimethylamino-3,10,12,12A-TETRAHYDROXY-7-[(METHOXY(METHYL)AMINO)-METHYL]-1,11-Dioxo-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-2-Carboxylic Acid Amide and Methods of Using the Same In force · High confidence | Allergan Pharmaceuticals International Limited | In force | High confidence | |
| US 8,969,589 | Compounds Acting at Multiple Prostaglandin Receptors Giving a General Anti-Inflammatory Response In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 8,927,544 | BENZOFURAN-2-Sulfonamides Derivatives as Chemokine Receptor Modulators In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 9,550,746 | BENZOFURAN-2-Sulfonamides Derivatives as Chemokine Receptor Modulators In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 9,567,328 | Compounds Acting at Multiple Prostaglandin Receptors Giving a General Anti-Inflammatory Response In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 8,889,870 | Kinase Inhibitors Grace period ended Nov 18, 2026 · lapse expected · Low confidence | Allergan, Inc. | Grace period ended Nov 18, 2026 lapse expected | Low confidence | |
| US 9,388,176 | Method of Treating Conditions with Kinase Inhibitors In force · High confidence | Allergan, Inc. | In force | High confidence | |
| 48 more term ends in 2033 · Pro | |||||
10 of 58 patents shown. Soonest term end first, then patent number.
Pro members see all 58.
45 of these are in force and held by Allergan, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.